GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Kimia Biosciences Ltd (BOM:530313) » Definitions » Return-on-Tangible-Asset

Kimia Biosciences (BOM:530313) Return-on-Tangible-Asset : 0.00% (As of . 20)


View and export this data going back to 2017. Start your Free Trial

What is Kimia Biosciences Return-on-Tangible-Asset?

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Kimia Biosciences's annualized Net Income for the quarter that ended in . 20 was ₹ Mil. Kimia Biosciences's average total tangible assets for the quarter that ended in . 20 was ₹ Mil. Therefore, Kimia Biosciences's annualized Return-on-Tangible-Asset for the quarter that ended in . 20 was 0.00%.

The historical rank and industry rank for Kimia Biosciences's Return-on-Tangible-Asset or its related term are showing as below:

BOM:530313's Return-on-Tangible-Asset is not ranked *
in the Drug Manufacturers industry.
Industry Median: 1.93
* Ranked among companies with meaningful Return-on-Tangible-Asset only.

Kimia Biosciences Return-on-Tangible-Asset Historical Data

The historical data trend for Kimia Biosciences's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kimia Biosciences Return-on-Tangible-Asset Chart

Kimia Biosciences Annual Data
Trend
Return-on-Tangible-Asset

Kimia Biosciences Semi-Annual Data
Return-on-Tangible-Asset

Competitive Comparison of Kimia Biosciences's Return-on-Tangible-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, Kimia Biosciences's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kimia Biosciences's Return-on-Tangible-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Kimia Biosciences's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where Kimia Biosciences's Return-on-Tangible-Asset falls into.



Kimia Biosciences Return-on-Tangible-Asset Calculation

Kimia Biosciences's annualized Return-on-Tangible-Asset for the fiscal year that ended in . 20 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: . 20 )  (A: . 20 )(A: . 20 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: . 20 )  (A: . 20 )(A: . 20 )
=/( (+)/ )
=/
= %

Kimia Biosciences's annualized Return-on-Tangible-Asset for the quarter that ended in . 20 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: . 20 )  (Q: . 20 )(Q: . 20 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: . 20 )  (Q: . 20 )(Q: . 20 )
=/( (+)/ )
=/
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is one times the annual (. 20) net income data.


Kimia Biosciences  (BOM:530313) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


Kimia Biosciences Return-on-Tangible-Asset Related Terms

Thank you for viewing the detailed overview of Kimia Biosciences's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Kimia Biosciences Business Description

Traded in Other Exchanges
N/A
Address
Netaji Subhash Place, 974, 9th Floor, Aggarwal Millenium Tower-II, Pitampura, New Delhi, IND, 110 034
Kimia Biosciences Ltd is a company engaged in the manufacturing of bulk drugs. Some of the company's products include Azelnidipine, Deflazacort, Oxaceprol, Seratodast, and Tretinoin among others. Its only operating segment being Pharmaceuticals.

Kimia Biosciences Headlines

No Headlines